Clinical Trials - India
-
IMPAACT 2034 - Phase I Study of the Pharmacokinetics, Safety, and Acceptability of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children with Rifampicin-Resistant Tuberculosis
Study Location: India
Eligibility: Ages Eligible for Study: up to 17 Years (Child ) Sexes Eligible for Study: Female Accepts Healthy Volunteers: No
Enrollment: Open
-
A5384: A Phase II, Randomized, Open-Label Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents with Tuberculous Meningitis
Study Location: India
Eligibility: Target Participant Age 15 years and older Definite, probable, or possible TBM diagnosis from testing performed as part of...
Enrollment: Open
-
Identification of Biomarkers That Can Predict Progression from Latent Tuberculosis Infection to Active Tuberculosis Disease
Study Location: India
Eligibility: Adult, Pediatric, Household contacts
Enrollment: Open
-
ACTIV-2/A5401: Adaptive Platform Treatment for Outpatients with COVID-19 (Adapt Out COVID)
Study Location: BaltimoreIndia
Eligibility: Adults
Enrollment: Open
-
P2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs during Pregnancy and Postpartum
Study Location: BaltimoreIndia
Eligibility: Preg/postpartum women. Infants
Enrollment: Open
-
The Pharmacokinetics, Safety and Acceptability of New Child-Friendly Formulations of Clofazimine and Moxifloxacin in Children Routinely Treated for Rifampicin-Resistant Tuberculosis (CATALYST)
Study Location: India
Eligibility: Pediatrics
Enrollment: Open
-
Impact of Tuberculosis Infection on HIV-1 Antibody Response (NWCS501)
Study Location: BaltimoreIndia
Eligibility: Adults, adolescents
Enrollment: Open
-
A5300B/I2003B/PHOENIX, Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients
Study Location: India
Eligibility: Men and women age greater than or equal to 18 year
Enrollment: Open
-
P2010: Phase III Study of the Virologic Efficacy and Safety of Dolutegravir-Containing versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and their Infants
Study Location: India
Eligibility: HIV-1-infected pregnant women initiating antiretroviral therapy at 14-28 weeks gestation, and their infants
Enrollment: Closed
-
P2005: A Phase I/II Open-Label, Single-Arm Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination with OBR for MDR-TB in HIV-Infected and Uninfected Children with MDR-TB
Study Location: India
Eligibility: HIV-infected and HIV-uninfected infants, children, and adolescents less than 18 years of age with confirmed or probable MDR-TB.
Enrollment: Open
-
A5253: Sensitivity and Specificity of Mycobacterium Tuberculosis Screening and Diagnostics in HIV-Infected Individuals
Study Location: India
Eligibility: Ages Eligible for Study: 13 Years and older (Child, Adult, Senior) Sexes Eligible for Study: All Accepts...
Enrollment: Closed
-
A5207, Maintaining Options for Mothers Study (MOMS): A Phase II Randomized Comparison of Three Antiretroviral Strategies Administered for 7 or 21 Days to Reduce the Emergence of Nevirapine Resistant HIV-1 Following a Single Intrapartum Dose of Nevirapine
Study Location: India
Eligibility: Ages Eligible for Study: 13 Years and older (Child, Adult, Senior) Sexes Eligible for Study: Female...
Enrollment: Closed
-
P1070, Dose-Finding and Pharmacogenetic Study of Efavirenz in HIV-Infected and HIV/TB Co-Infected Infants and Children ≥ 3 Months to < 36 Months of Age
Study Location: India
Eligibility: Ages Eligible for Study: 3 Months to 35 Months (Child) Sexes Eligible for Study: All Accepts Healthy...
Enrollment: Closed
-
A5290, A Randomized, Phase 2b Study of a Double-Dose Lopinavir/Ritonavir-Based Antiretroviral Regimen with Rifampin-Based Tuberculosis Treatment versus a Standard-Dose Lopinavir/Ritonavir-Based Antiretroviral Regimen with Rifabutin-Based Tuberculosis Treatment with or without Raltegravir in HIV-1-Infected Persons Requiring Treatment for Active TB and HIV
Study Location: India
Eligibility: Ages Eligible for Study: 18 Years and older (Adult, Senior) Sexes Eligible for Study: All Accepts Healthy...
Enrollment: Closed
-
A5279, Phase III Clinical Trial of Ultra-Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-infected Individuals with Latent Tuberculosis Infection
Study Location: India
Eligibility: Ages Eligible for Study: 13 Years and older (Child, Adult, Senior) Sexes Eligible for Study: All Accepts...
Enrollment: Closed
-
A5302: BioBank for Surrogate Marker Research for TB (B-SMART)
Study Location: India
Eligibility:
Enrollment: Closed
-
NWCS 445: Novel Biomarkers to Shorten TB Treatment NWCS 445: Novel Biomarkers to Shorten TB Treatment: A Substudy of S31/A5349
Study Location: India
Eligibility: Partncipants enrolled in “Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: a randomized,...
Enrollment: Closed
-
NWCS 414, Evaluation of a Serum Biosignature for Identifying HIV-infected Individuals at Greatest risk for Developing Active TB
Study Location: India
Eligibility: N/A
Enrollment: Closed
-
P1108: A Phase I/II, Open-Label, Single Arm Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Bedaquiline (BDQ) in Combination with Optimized Individualized Multidrug-Resistant Tuberculosis (MDR-TB) Therapy in HIV-Infected and HIV-Uninfected Infants, Children and Adolescents with MDR-TB Disease
Study Location: India
Eligibility: Ages Eligible for Study: up to 18 Years (Child, Adult) Sexes Eligible for Study: All Accepts Healthy...
Enrollment: Open
-
NWCS 408: Examining Longitudinal Cytokine Profiles in HIV-TB Co-infected Participants Examining Longitudinal Cytokine Profiles in HIV-TB Co-infected Participants to Study the Exit from Latent TB Infection and Death: A Supplemental Proposal for A5274
Study Location: India
Eligibility:
Enrollment: Closed
-
A5349: Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: A randomized, open-label, controlled phase 3 clinical trial (TBTC S31)
Study Location: India
Eligibility: Ages Eligible for Study: 12 Years and older (Child, Adult, Senior) Genders Eligible for Study: Both Accepts...
Enrollment: Closed
-
A5300/P2003: PHOENIx Feasibility Study
Study Location: India
Eligibility: Feasibility Study; N/A
Enrollment: Closed
-
A5332: Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)
Study Location: BaltimoreIndia
Eligibility: HIV infected men and women between the ages of 40 and 75 On HIV medications for at least 6 months CD4 cell count greater...
Enrollment: Closed
-
A5225: Phase I/II Dose-Finding Study of High-Dose Fluconazole Treatment in AIDS-Associated Cryptococcal Meningitis
Study Location: India
Eligibility: HIV-infected males and females ≥16 years of age presenting with their first episode of CM. Participants may not have received...
Enrollment: Closed
-
A5273: Multicenter Study of Options for Second-Line Effective Combination Therapy (SELECT)
Study Location: India
Eligibility: Human immunodeficiency virus (HIV)-1 infected adults (age ≥18 years) who have confirmed virologic failure on an...
Enrollment: Closed
-
A5274: REMEMBER, Reducing Early Mortality and Early Morbidity by Empiric Tuberculosis Treatment Regimens
Study Location: India
Eligibility: Participating sites must have a regional TB incidence (i.e., the TB incidence within the site’s expected catchment area)...
Enrollment: Closed
-
A5282: A Randomized, Phase II Trial to Compare an HPV Test-and-Treat Strategy to a Cytology-Based Strategy for Prevention of CIN 2+ in HIV-Infected Women
Study Location: India
Eligibility: HIV-infected women 18 years of age or older. Eligible participants should have no history of major cervical procedures or...
Enrollment: Closed
-
A5288: MULTIOCTAVE, Management Using the Latest Technologies in Resource-limited Settings to Optimize Combination Therapy After Viral Failure
Study Location: India
Eligibility: HIV-1-infected males and females at non-US sites, aged ≥18 years, who have experience with or resistance to NRTIs, NNRTIs,...
Enrollment: Closed
-
P1060: Phase II, parallel, randomized, clinical trials comparing the responses to initiation of NNRTI-based antiretroviral therapy in HIV-infected infants who have not previously received Single dose Nevirapine for prevention of Mother-to-child HIV transmission
Study Location: India
Eligibility: HIV-infected infants and children ≥ 2 months to < 36 months of age who are eligible for ART as defined by the WHO...
Enrollment: Closed
-
P1073: Study of Immune Reconstitution Inflammatory Syndrome (IRIS) for International Sites Initiating Highly Active Antiretroviral Therapy (HAART) in Infants and Children < 72 Months of Age
Study Location: India
Eligibility: Ages Eligible for Study: up to 72 Months (Child) Sexes Eligible for Study: All Accepts Healthy Volunteers:...
Enrollment: Closed
-
P1077BF: Breastfeeding Version of the PROMISE Study (Promoting Maternal and Infant Survival Everywhere)
Study Location: India
Eligibility: Antepartum component - Pregnant HIV-infected women who intend to breastfeed and their infants. Late Presenters - Late...
Enrollment: Closed
-
P1077FF: Formula Feeding Version of the PROMISE Study (Promoting Maternal and Infant Survival Everywhere)
Study Location: India
Eligibility: Antepartum Component – HIV-infected pregnant women who intend to formula feed (FF) (with and without HBV) with documented...
Enrollment: Closed
-
P1078: A Phase IV Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Safety of Immediate (Antepartum-Initiated) Versus Deferred (Postpartum-Initiated) Isoniazid Preventive Therapy Among HIV-Infected Women in High TB Incidence Settings
Study Location: India
Eligibility: Mother/infant pairs: HIV-infected pregnant women ≥ 14 weeks through ≤ 34 weeks (34 weeks, 6 days) gestation.
Enrollment: Closed